For research use only. Not Intended for Therapeutic Use!
|We would like to match the lowest price on market if possible.|
The (+)-DHMEQ, the distomer of DHMEQ, is a inhibitor of NF-κB.
In vitro: (+)-DHMEQ down-regulat the NF-κB target genes IRF4 and CD40, the secretion of IL-6, CCL5, CCL17 and generated ROS. Cytotoxicity, CD30 down-modulation and CD30 shedding by (+)-DHMEQ are prevented by ROS scavenger NAC.  (+)-DHMEQ is a novel NF-κB inhibitor that induces apoptosis and cell-cycle arrest in several cancer cell types and promotes ROS generation, which causes genotoxic DNA damage in human liver cells. 
. Celegato M et al. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironmentand synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett. 2014 Jul 10;349(1):26-34.
. Lampiasi N et al. Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells. Biochim Biophys Acta. 2014 Nov;1843(11):2662-73.
. Matsumoto N et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000 May 1;10(9):865-9.
. Yoshikazu Suzuki et al. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron. Tetrahedron 60 (2004) 7061-7066